^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Parsortix Liquid Biopsy

    Company:
    ANGLE
    Type:
    FDA Approved
    Related tests:

    Details

    Evidence
    News
    Parsortix Liquid Biopsy is a simple blood test for personalised cancer care. It is a a non-invasive, repeatable, low cost procedure. 51 actionable genes were identified in the CTCs including the 39 most frequently mutated genes in metastatic breast cancer.
    Cancer:
    Breast Cancer
    Gene:
    PD-L1 (Programmed death ligand 1)
    Drug:
    Tagrisso (osimertinib)
    Method:
    Circulating Tumor DNA (ctDNA)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    05/24/22
    BC
    -
    FDA
    Confirmatory trial(s)
    HOMING
    ,
    NCT03427450
    |
    PLoS One